Company Overview
Company Type: Public Company
Website: www.nervgen.com
Number of Employees: -
Ticker: NGEN (TSXV)
Year Founded: 2017


Business Description
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company’s lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
111.9
EBITDA
(21.2)
Total Enterprise Value
96.0
TEV/EBITDA
NM
EBIT
(21.2)
Cash & ST Invst.
16.1
P/Diluted EPS Before Extra
NM
Net Income
(18.9)
Total Debt
0.2
Price/Tang BV
15.6x
Capital Expenditure
0.0
Total Assets
17.4
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
-
-
(0.31)
(0.30)
(0.31)
Revenue (mm)
-
-
0.00
0.00
0.00
EBITDA (mm)
-
-
(14.70)
(15.80)
(14.70)

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/EBITDA
NM

Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
5.00
Potential Upside
168.82%


Key Professionals
Name
Title
Radvak, William Joseph
Co-Founder & Chairman
Kelly, Michael 
CEO, President & Director
McAlister, Brian 
Co-Founder & Advisor
Punnett, Harold Martin
Co-Founder & Independent Director
Adams, William J.
CFO & Corporate Secretary
Mikol, Daniel D.
Chief Medical Officer

Key Board Members
Name
Title
Radvak, William Joseph
Co-Founder & Chairman
Kelly, Michael 
CEO, President & Director
McAlister, Brian 
Co-Founder & Advisor
Punnett, Harold Martin
Co-Founder & Independent Director
Ives, Glenn Antony
Independent Director
Antel, Jack 
Multiple Sclerosis Clinical Advisory Board
Bayley, Brian Eric
Independent Director
Chataway, Jeremy 
Multiple Sclerosis Clinical Advisory Board
Cohen, Jeffrey K.
Multiple Sclerosis Clinical Advisory Board
Cummings, Jeffrey L.
Member of Alzheimer's Disease Scientific Advisory Board
Davis, Michael 
Advisor
Farlow, Martin Rhys
Member of Alzheimer's Disease Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
2955 Virtual Way Suite 480 | Vancouver, BC | V5M 4X6 | Canada
Phone: 778-731-1711   

Current and Pending Investors
C S Bio Company, Inc (Pending), PFP Biosciences Holdings

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 1.86
Market Cap (mm)
110.7
Open
 1.89
Shares Out. (mm)
59.5
Previous Close
 1.86
Float %
78.3%
Change on Day
(0.02)
Shares Sold Short (mm)
-
Change % on Day
(1.1)%
Dividend Yield %
-
Day High/Low
 1.92/ 1.86
Diluted EPS Excl. Extra Items
(0.32)
52 wk High/Low
 2.27/ 1.50
P/Diluted EPS Before Extra
NM
Volume (mm)
0.03
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
1.56


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
TSXV:NGEN - Common Stock


Index Membership
S&P/TSX Venture Composite Index;S&P/TSX Venture Health Care (Sector) Index (CAD);S&P/TSX Venture Pharmaceuticals, Biotechnology & Life Sciences (Industry Group) Index (CAD)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-30-2022
Jul-13-2022
Private Placement
Target
NervGen Pharma Corp. (TSXV:NGEN)
PFP Biosciences Holdings

15.23
May-16-2022
-
Shelf Registration
Target
NervGen Pharma Corp. (TSXV:NGEN)


77.47
Nov-29-2021
Nov-29-2021
Private Placement
Target
NervGen Pharma Corp. (TSXV:NGEN)


1.81
Nov-4-2021
Nov-12-2021
Public Offering
Target
NervGen Pharma Corp. (TSXV:NGEN)


6.37
Aug-04-2021
Aug-05-2021
Private Placement
Target
NervGen Pharma Corp. (TSXV:NGEN)


1.88
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-25-2023
Product-Related Announcements
NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
Sep-14-2023
Company Conference Presentations
NervGen Pharma Corp. Presents at 2023 International Spinal Research Trust Network Meeting, Sep-14-2023
Sep-13-2023
Company Conference Presentations
NervGen Pharma Corp. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-13-2023 04:00 PM
Aug-24-2023
Special Calls
NervGen Pharma Corp. - Special Call
Aug-08-2023
Product-Related Announcements
Nervgen Pharma Corp. Receives Institutional Review Board Approval for Its Phase 1B/2A Proof-Of-Concept Clinical Trial Protocol of Its Proprietary Lead Compound, Nvg-291, in Individuals with Spinal Cord Injury


Advisors
Most Recent Auditor
KPMG Limited
Private Placement Advisors
Dorsey & Whitney LLP
Public Offering Advisors
Blake, Cassels & Graydon LLP, Davidson & Company LLP, Dorsey & Whitney LLP, Northwest Law Group


Most Recent Auditor
KPMG LLP - Klynveld Peat Marwick Goerdeler


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 15, 2023 09:29 AM
NGEN
NervGen Pharma Corp (NGEN.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
87
GlobalData

Sep 13, 2023 02:15 AM
NGEN
NervGen Pharma Corp (NGEN.CVE) - Financial Analysis Review
Reports
182
GlobalData

Aug 25, 2023 03:25 AM
NGEN
NervGen Pharma Corp (NGEN.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
62
GlobalData

Jun 09, 2023 06:27 AM
NGEN
NervGen Pharma Corp (NGEN.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
84
GlobalData

Jun 08, 2023 05:00 AM
NGEN
NervGen Pharma Corp (NGEN.CVE) - Financial Analysis Review
Reports
173
GlobalData

Apr 26, 2023 07:05 AM
NGEN
NervGen Pharma Corp (NGEN.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
57
GlobalData

Mar 29, 2023 04:45 AM
NGEN
NervGen Pharma Corp (NGEN.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
52
GlobalData

Mar 10, 2023 04:05 AM
NGEN
NervGen Pharma Corp (NGEN.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
77
GlobalData

Mar 09, 2023 01:56 AM
NGEN
NervGen Pharma Corp (NGEN.CVE) - Financial Analysis Review
Reports
163
GlobalData

Dec 13, 2022 06:22 AM
NGEN
NervGen Pharma Corp (NGEN.CVE) - Financial Analysis Review
Reports
162


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


PFP Biosciences Holdings

10,000,000

16.80

19.3

Apr-28-2023


Radvak BASc, William Joseph

1,288,500

2.17

2.5

Sep-27-2023


Punnett D.M.D., Harold Martin

1,000,000

1.68

1.9

May-23-2023


Bayley MBA, Brian Eric

450,000

0.76

0.9

May-23-2023


Adams C.A., CPA, CA, CPA, William J.

111,750

0.19

0.2

Apr-28-2023


Ives, Glenn Antony

50,000

0.08

0.1

May-23-2023


Rogers M.D., Adam H.

10,000

0.02

0.0

May-23-2023


FNY Investment Advisers, LLC

3,400

0.01

0.0

Jun-30-2023



 



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Radvak BASc, William Joseph
1,288,500
(1,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-12
NervGen Pharma To Present At 2023 International Spinal Research Trust Network Meeting
India Pharma News
Sep-06
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference
ENP Newswire


Company Coverage
This company is not on any Coverage List.

Products
NVG-291 (Future), Pharmaceutical Drugs (Future)


Upcoming Events
Date/Time
Type
Nov-09-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-25-2023
-
NervGen Pharma Corp. (TSXV:NGEN)
SEDAR
News Releases
58 KB
Sep-25-2023
-
NervGen Pharma Corp. (TSXV:NGEN)
SEDAR
News Releases
58 KB
Sep-11-2023
-
NervGen Pharma Corp. (TSXV:NGEN)
SEDAR
News Releases
44 KB
Sep-05-2023
-
NervGen Pharma Corp. (TSXV:NGEN)
SEDAR
News Releases
45 KB
Aug-22-2023
-
NervGen Pharma Corp. (TSXV:NGEN)
SEDAR
News Releases
45 KB
Aug-09-2023
-
NervGen Pharma Corp. (TSXV:NGEN)
SEDAR
News Releases
62 KB
Aug-09-2023
Jun-30-2023
NervGen Pharma Corp. (TSXV:NGEN)
SEDAR
Interim Financial Statements
294 KB
Aug-08-2023
-
NervGen Pharma Corp. (TSXV:NGEN)
SEDAR
News Releases
59 KB
Jul-04-2023
-
NervGen Pharma Corp. (TSXV:NGEN)
SEDAR
Material Change Report
19 KB
Jun-27-2023
-
NervGen Pharma Corp. (TSXV:NGEN)
SEDAR
News Releases
62 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Radvak BASc, William Joseph (Co-Founder & Chairman)
Sep-27-2023
Common Shares
(1,000)
(2,034)
Open Market Disposition
(0.08)
Multiple
Punnett D.M.D., Harold Martin (Co-Founder & Independent Director)
Feb-28-2023
Common Shares
(1,450,000)
0
Other Disposition
(59.18)
Multiple
Radvak BASc, William Joseph (Co-Founder & Chairman)
Aug-19-2022
Common Shares
(5,500)
(11,914)
Open Market Disposition
(0.42)
Multiple
Brennan B.Sc., M.Sc., Paul Anthony (Former President, CEO & Director)
May-04-2022
Common Shares
50,000
85,683
Derivative Exercise and Retained Stock
8.78
Multiple
Adams C.A., CPA, CA, CPA, William J. (CFO & Corporate Secretary)
Apr-27-2022
Common Shares
48,000
82,159
Derivative Exercise and Retained Stock
75.29
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Radvak, William Joseph
Co-Founder & Chairman
604 488-5417
-
bradvak@nervgen.com
Kelly, Michael 
CEO, President & Director
778-731-1711
-

McAlister, Brian 
Co-Founder & Advisor
778-731-1711
-

Punnett, Harold Martin
Co-Founder & Independent Director
778-731-1711
-

Ives, Glenn Antony
Independent Director
778-731-1711
-

Antel, Jack 
Multiple Sclerosis Clinical Advisory Board
778-731-1711
-

Bayley, Brian Eric
Independent Director
778-731-1711
-

Chataway, Jeremy 
Multiple Sclerosis Clinical Advisory Board
778-731-1711
-

Cohen, Jeffrey K.
Multiple Sclerosis Clinical Advisory Board
778-731-1711
-

Cummings, Jeffrey L.
Member of Alzheimer's Disease Scientific Advisory Board
778-731-1711
-

Davis, Michael 
Advisor
778-731-1711
-

Farlow, Martin Rhys
Member of Alzheimer's Disease Scientific Advisory Board
778-731-1711
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Radvak, William Joseph
Co-Founder & Chairman
604 488-5417
-
bradvak@nervgen.com
Kelly, Michael 
CEO, President & Director
778-731-1711
-

McAlister, Brian 
Co-Founder & Advisor
778-731-1711
-

Punnett, Harold Martin
Co-Founder & Independent Director
778-731-1711
-

Adams, William J.
CFO & Corporate Secretary
778-731-1711
-
badams@nervgen.com
Mikol, Daniel D.
Chief Medical Officer
778-731-1711
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
